Name: MILESTONE PHARMACEUTICALS IN (MIST) Stock
Brand: MILESTONE PHARMACEUTICALS IN
Rating: 5.5 (3 reviews)

MIST Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Chartmill - Mentions: IRBT NCI CV OPTT ...

Monday's pre-market session: top gainers and losers

6 days ago - By: Chartmill - Mentions: FEIM DXLG CGC TLRY ...

Let's take a look at the stocks that are in motion in today's session.

3 days ago - By: Stocktwits

MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns

6 days ago - By: Milestone Pharmaceuticals Inc.

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

16 days ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

2 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

2 months ago - By: Milestone Pharmaceuticals Inc.

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

4 months ago - By: Milestone Pharmaceuticals Inc.

Milestone® Pharmaceuticals to Present at Upcoming Conferences

4 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

5 months ago - By: Benzinga - Mentions: WDFC AGM SGN TMDX ...

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

5 months ago - By: Benzinga - Mentions: CALC KPTI CAPR ATHE ...

12 Health Care Stocks Moving In Friday's Intraday Session

5 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

5 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces Proposed Public Offering

5 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

7 months ago - By: Zacks Investment Research

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

7 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

9 months ago - By: Yahoo Finance - Mentions: TSLA BLK

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen

9 months ago - By: Yahoo Finance - Mentions: ICON LTRY APTO META ...

Icon Energy to effect 1-for-40 reverse stock split

9 months ago - By: Yahoo Finance - Mentions: APTO WGO BRZE IDXX ...

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright

9 months ago - By: Yahoo Finance - Mentions: RJF WFC BRZE LVLU ...

Braze price target raised to $55 from $50 at Citi

9 months ago - By: Stocktwits - Mentions: GWX NVDA

MILESTONE PHARMACEUTICALS IN (MIST) Stock News

MIST Latest News, Press Relases and Analysis

Monday's pre-market session: top gainers and losers

Let's take a look at the stocks that are in motion in today's session.

MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

12 Health Care Stocks Moving In Friday's Intraday Session

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Milestone Pharmaceuticals Announces Proposed Public Offering

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen

Icon Energy to effect 1-for-40 reverse stock split

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright

Braze price target raised to $55 from $50 at Citi

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive